Metsera, Inc. (NASDAQ:MTSR - Get Free Report)'s share price traded up 7.6% during mid-day trading on Monday . The company traded as high as $28.28 and last traded at $27.12. 40,441 shares were traded during mid-day trading, a decline of 93% from the average session volume of 557,944 shares. The stock had previously closed at $25.21.
Analysts Set New Price Targets
Several brokerages recently commented on MTSR. Cantor Fitzgerald assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an "overweight" rating for the company. Guggenheim assumed coverage on Metsera in a research report on Tuesday, February 25th. They issued a "buy" rating and a $56.00 target price on the stock. Bank of America began coverage on Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $38.00 price target for the company. Finally, Evercore ISI assumed coverage on Metsera in a research note on Tuesday, February 25th. They set an "outperform" rating for the company.
View Our Latest Analysis on MTSR
Metsera Price Performance
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
